Evidence map›Paper›PMID 41050080›Full record

ArticleOncology research2025

Competitive Sequestration of miR-1183 by lncRNA DDX11-AS1 Drives Gliomagenesis through E2F7 Activation.

Jianwei Wang, Xinzhi Yang, Lvbiao Lin, Jianbo Yu, Jie Mao

Abstract read
In one paragraph

Article in Oncology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jianwei WangDepartment of Neurosurgery, Shenzhen Hospital, Southern Medical University, Shenzhen, 518100, China.
Xinzhi YangDepartment of Neurosurgery, Shenzhen Yantian District People's Hospital, Shenzhen, 518100, China.
Lvbiao LinDepartment of Neurosurgery, Longgang Central Hospital of Shenzhen, Shenzhen, 518100, China.
Jianbo YuDepartment of Pathology, Longgang Central Hospital of Shenzhen, Shenzhen, 518100, China.
Jie MaoDepartment of Neurosurgery, Longgang Central Hospital of Shenzhen, Shenzhen, 518100, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Glioma, as the most lethal primary brain malignancy with poor prognosis, requires further elucidation on the functional role of long noncoding RNA (lncRNA) DDX11 antisense RNA 1 (DDX11-AS1) in its pathogenesis, despite its established oncogenic functions in other cancers. Therefore, this study sought to characterize the oncogenic role and molecular mechanism of DDX11-AS1 in glioma. Methods: DDX11-AS1 expression levels were analyzed in clinical surgical glioma specimens and publicly available datasets. The functional roles of DDX11-AS1 on glioma cell proliferation and migration were investigated using Results: DDX11-AS1 expression was markedly upregulated in clinical glioma specimens. Functionally, DDX11-AS1 knockdown significantly suppressed glioma cell proliferation and migration Conclusions: This study demonstrates that lncRNA DDX11-AS1 promotes glioma progression by regulating the miR-1183/E2F7 axis, indicating a potential therapeutic target for glioma.

Indexed as

Brain NeoplasmsDEAD-box RNA HelicasesE2F7 Transcription FactorGliomaMicroRNAsRNA, Long NoncodingAnimalsCarcinogenesisCell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticHumansMiceDEAD-box RNA HelicasesE2F7 protein, humanE2F7 Transcription FactorMicroRNAsRNA, Long Noncodingcompetitive endogenous RNADDX11 antisense RNA 1E2F transcription factor 7GliomamiR-1183

Identifiers

PMID41050080
PMCPMC12494103

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.